Last reviewed · How we verify

NCT07123896

Arrhythmia Cohort Study

Not yet recruiting Last updated 14 August 2025
What this trial tests

trial testing Normal treatment with catheter ablation or medicine in Arrhythmia in 10,000 participants. Not yet recruiting.

Timeline
24 August 2025
Primary endpoint
24 July 2030
24 July 2030

Quick facts

Lead sponsorBeijing Anzhen Hospital
StatusNot yet recruiting
Study typeOBSERVATIONAL
Enrollment10,000
Start date24 August 2025
Primary completion24 July 2030
Estimated completion24 July 2030
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Beijing Anzhen Hospital

Who can join

Adults 18 to 90, any sex, with Arrhythmia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this prospective, observational registry study is to evaluate the long-term effectiveness, safety, and impact of different kinds of treatment on the quality of life across diverse arrhythmia subtypes and patient populations in hospitalized adults with cardiac arrhythmias (including atrial fibrillation, atrial flutter, supraventricular tachycardia, and ventricular arrhythmias) undergoing routine clinical care.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Arrhythmia

Currently open trials in the same condition.

Other Beijing Anzhen Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07123896.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing